Ferric Citrate, an Iron-Based Phosphate Binder, Reduces Health Care Costs in Patients on Dialysis Based on Randomized Clinical Trial Data
Conclusions
Phosphate binding with FC reduces IV iron and ESA usage. Given the high cost burden of ESRD, our model demonstrates significant potential cost savings.
Trial Registration
ClinicalTrials.gov (NCT01191255) http://clinicaltrials.gov/ct2/show/NCT01191255.
Source: Drugs in R&D - Category: Drugs & Pharmacology Source Type: research
More News: Anemia | Calcium | Clinical Trials | Dialysis | Drugs & Pharmacology | Health | Health Management | Managed Care | Medicare | Renvela | Study